|
Product complaint # (b)(4).Date sent to the fda: 2/21/2025.Corrected information: d4 udi.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|
|
Product complaint # (b)(4).This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.A manufacturing record evaluation was performed for the finished device lot, and no non-conformances were identified.Additional information was requested, and the following was obtained via: additional information in note (b)(6) states that 7 products are involved; however, it also states that about half of (b)(4) sutures of the package were broken.Please clarify: how many sutures were broken? half of (b)(4) strands in a pac broke.Also, the actual samples are (b)(4).What is the lot number of each broken suture (101rgs, 1022q1, 101gx2, other)? unk.When did each suture break (in the package, during removal from package, during handling prior to use on patient or during use on the patient)? please specify: during use on the patient.Please perform and document the follow up attempt for product return.Please document the shipment tracking number in notes or rmao sections.The device has been received at (b)(6) and will be shipped.Please check rmao.Tracking number: (b)(4).Please provide the source or name and title of external person providing answers to follow-up (external person submitting answers to sales rep or loc/bq) =(b)(6).We got this info from the sales-rep on nov_1_2024.-qty to be returned of ip-02209740: (b)(4) (lot#: 101rgs).-qty of product involved of ip-02209740: (b)(4) (lot#: 101rgs x2packs, 1022q1 x4packs, 101gx2 x1pack).-additional event information about half of the (b)(4) sutures of the package were broken when tried to ligate.One package will be returned with the same lot number of sutures as the lot number: (b)(4) of the product involved.Attempts are being made to obtain the following information.To date no response has been provided.If further details are received at a later date a supplemental medwatch will be sent.H3 investigation summary: the product was returned for evaluation.Two empty foil packets were received for analysis.Product code vcp713d.The visual assessment of the returned winding former.No suture and needle were returned for analysis.As per this condition, the event described could not be confirmed.If additional information is made available, the investigation will be updated as applicable.As part of our quality process, the manufacturing records of this lot-serial number were reviewed, and the manufacturing standards were met prior to the release of this batch.As part of the ethicon quality process, all devices are manufactured, inspected, and released to approved specifications.D4: full udi currently unavailable since the exact lot of the suspected device cannot be determined.
|
|
It was reported that a patient underwent an unknown neurosurgery procedure on (b)(6) 2024 and suture was used.During the procedure, it was reported by a sales rep that, during closing the head, it was tried to suture and then ligate, but the suture was broken.Details are being confirmed.It was a control release needle.No adverse patient consequences were reported.Additional information was requested.
|